Inhibition of rat colon tumors by sulindac and sulindac sulfone is independent of K-ras (codon 12) mutation

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 278, Issue 2 41-2, 2000, Pages

  De Jong, Tanya A ^a   Skinner, Stewart A ^a,b   Malcontenti Wilson, Cathy ^a   Vogiagis, Daphne ^a   Bailey, Michael ^a   Van Driel, Ian R ^a   O'Brien, Paul E ^a  

^a MONASH UNIVERSITY MEDICAL SCHOOL   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

1,2 dimethylhydrazine dihydrochloride; Colorectal cancer; Nonsteroidal anti inflammatory drugs

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC; SULINDAC SULFONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CHEMOPROPHYLAXIS; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; GENE MUTATION; MALE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; RAT;

EID: 0034058848     PISSN: 01931857     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpgi.2000.278.2.g266     Document Type: Article

References (45)

1. Arber, N., E, K. H. Han, A. Sgambato, G. A. Piazza, T. M. Delohery, M. Begemann, C. M. Weghorst, N. H. Kim, R. Pamukcu, D. J. Ahnen, J. C. Reed, I. B. Weinstein, and P. R. Holt. A K-ras oncogene increases resistance to sulindac-induced apoptosis in rat enterocytes. Gastroenterology 113: 1892-1900, 1997.
2. Bird, R. P. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen - preliminary findings. Cancer Lett. 37: 147-151, 1987.
3. Boolbol, S. K., A. J. Dannenberg, A. Chadburn, C. Martucci, X. J. Guo, J. T. Ramonetti, M. Abreu-Goris, H. L. Newmark, M. L. Lipkin, J. J. DeCosse, and M. Bertagnolli. Cyclooxygenase-2 overexpression and tumour formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 56: 2556-2560, 1996.
4. Chan, T. A., P. J. Morin, B. Vogelstein, and K. W. Kinzler. Mechanisms underlying nonsteroidal antiinflammatory drug mediated apoptosis. Proc. Natl. Acad. Sci. USA 95: 681-686, 1998.
5. Chang, W. W. L. Pathogenesis and biological behaviour of 1,2-dimethylhydrazine-induced colonic neoplasms in the mouse. In: Cell Proliferation in the GI Tract, edited by D. R. Appleton, J. P. Sunter, and A. J. Watson. Tunbridge Wells, UK: Pitman, 1980, p. 278-297.
6. Charalambous, D., and P. E. O'Brien. Inhibition of colon cancer precursors in the rat by sulindac sulphone is not dependent on inhibition of prostaglandin synthesis. J Gastroenterol. Hepatol. 11: 307-310, 1996.
7. Charalambous, D., K. C. R. Farmer, and P. E. O'Brien. Sulindac and indomethacin inhibit formation of aberrant crypt foci in the colons of dimethyl hydrazine treated rats. J Gastroenterol. Hepatol. 11: 88-92, 1996.
8. Charalambous, D., S. A. Skinner, and P. E. O'Brien. Sulindac inhibits colorectal tumour growth, but not prostaglandin synthesis in the rat. J Gastroenterol. Hepatol. 13: 1195-1200, 1998.
9. Fearon, E. R., and B. Vogelstein. A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
10. Giardiello, F. M, J. A. Offerhaus, A. C. Tersmette, L. M. Hylind, A. J. Krush, J. D. Brensinger, S. V. Booker, and S. R. Hamilton. Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors. Gut 38: 578-581, 1996.
11. Goldberg, Y., I. I. Nassif, A. Pittas, L. L. Tsai, B. D. Dynlacht, B. Rigas, and S. J. Shiff. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumour suppressor and cell cycle regulatory proteins. Oncogene 12: 893-901, 1996.
12. Grand, R. J. A., and D. Owens. The biochemistry of ras p21. Biochem J. 279: 609-631, 1991.
13. Hanif, R., A. Pittas, Y. Feng, M. I. Koutsos, L. Qiao, L. Staiano-Coico, S. I. Shiff, and B. Rigas. Effects of nonsteroidal anti-inflammatory drugs on proliferation, and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol. 52: 237-245, 1991.
14. Herrmann, C., C. Block, C. Geisen, K. Haas, C. Weber, G. Winde, T. Moroy, and O. Muller. Sulindac sulfide inhibits Ras signaling. Oncogene 17: 1769-1775, 1998.
15. Jacoby, R. F., X. Llor, B. Teng, N. Davidson, and T. A. Brasitus. Mutations in the K-ras oncogene induced by 1,2 dimethylhydrazine in preneoplastic and neoplastic rat colonic mucosa. J. Clin. Invest. 87: 624-630, 1991.
16. Jouzeau, J. Y., B. Terlain, A. Abid, E. Nedelec, and P. Netter. Cyclo-oxygenase isoenzymes: how recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 53: 563-582, 1997.
17. Kumar, R., and L. L. Dunn. Designed diagnostic restriction fragment length polymorphisms for the detection of point mutations in ras oncogenes. Oncogene Res. 1: 235-241, 1989.
18. Kune, G. Causes and Control of Colorectal Cancer - A Model For Cancer Prevention. Boston, MA: Kluwer Academic, 1996.
19. Labayle, D., D. Fischer, P. Vielh, F. Drouhin, A. Pariente, C. Bories, O. Duhamel, M. Trousset, and P. Attali. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101: 635-639, 1991.
20. Llor, X., R. F. Jacoby, B Teng, N Davidson, M. D. Sitrin, and T. A. Brasitus. K-ras mutations in 1,2 dimethylhydrazine-induced colonic tumours: effects of supplemental dietary calcium, and vitamin D deficiency. Cancer Res. 51: 4305-4309, 1991.
21. Logan, R. F. A, J. Little, and J. D. Hardcastle. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. Br. Med. J. 307: 285-289, 1993.
22. Mahmoud, N. N., S. K. Boolbol, A. J. Dannenberg, S. K. Boolbol, A. J. Dannenberg, J. R. Mestre, R. T. Bilinski, C. Martucci, H. L. Newmark, A. Chadburn, and M. M. Bertagnolli. The sulfide metabolite of sulindac prevents tumours and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis 19: 87-91, 1998.
23. McLellan, E. A., R. A. Owen, K. A. Stepniewska, J. P. Sheffield, and N. R. Lemoine. High frequency of K-ras mutations in sporadic colorectal carcinomas Gut 34: 392-396, 1993.
24. Moorghen, M., P. Ince, K. J. Finny, J. P. Sunter, D. R. Appleton, and A. J. Watson. A protective effect of sulindac against chemically induced primary colonic tumours in mice. J. Pathol. 156: 341-347, 1989.
25. Moorghen, M. P. Ince, K. J. Finny, J. P. Sunter, A. J. Watson, and D. R. Appleton. The effect of sulindac on colonic tumour formation in dimethyhydrazine-treated mice. Acta Histochem. Suppl. 39: S195-S199, 1990.
26. Nugent, K. P., K. C. R. Farmer, A. D. Spigelman, C. B. Williams, and R. K. S. Phillips. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br. J. Surg. 80: 1618-1619, 1993.
27. Paganini-Hill, A., A. Chao, R. K. Ross, and B. E. Henderson. Aspirin use and chronic disease: a cohort study of the elderly. Br. Med. J. 299: 1247-1250, 1989.
28. Pasricha, P. J., A. Bedi, K. O'Connor, A. Rashid, A. J. Akhtar, M. L. Zahurak, S. Piantadosi, S. R. Hamilton, and F. M. Giardiello. The effects of sulindac on colorectal proliferation, and apoptosis in familial adenomatous polyposis. Gastroenterology 109: 994-998, 1995.
29. Piazza, G. A., D. S. Alberts, L. J. Hixson, N. S. Paranka, H. Li, T. Finn, C. Bogert, J. M. Guillen, K. Brendel, P. H. Gross, G. Sperl, J. Ritchie, R. W. Burt, L. Ellsworth, D. J. Ahnen, and R. Pamukcu. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. 57: 2909-2915, 1997.
30. Piazza, G. A., A. K. Rahm, T. S. Finn, B. H. Fryer, H. Li, A. L. Stoumen, R. Pamukcu, and D. J. Ahnen. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res. 57: 2452-2459, 1997.
31. Piazza, G. A., K. Rahm, M. Krutzsch, G. Sperl, N. S. Paranka, P. H. Gross, K. Brendel, R. W. Burt, D. S. Alberts, R. Pamukcu, and D. J. Ahnen. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 55: 3110-3116, 1995.
32. Pretlow, T. P., B. J. Barrow, W. S. Ashton, M. A. O'Riordan, T. G. Pretlow, J. A. Jurcisek, and T. A. Stellato. Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res. 51: 1564-1567, 1991.
33. Pretlow, T. P., T. A. Brasitus, N. C. Fulton, C. Cheyer, and E. L. Kaplan. K-ras mutations in putative preneoplastic lesions in human colon. J. Natl. Cancer Inst. 85: 2004-2007, 1993.
34. Rao, C. V., A. Rivenson, B. Simi, E. Zang, G. Kelloff, V. Steele, and B. S. Reddy. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res. 55: 1464-1472, 1995.
35. Samaha, S. S., G. J. Kelloff, V. Steele, C. V. Rao, and B. S. Reddy. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res. 57: 1301-1305, 1997.
36. Shiff, S. J., L. Qiao, L. L. Tsai, and B. Rigas. Sulindac sulfide, an aspirin like compound, inhibits proliferation, causes cell cycle quiescence and induces apoptosis in HT-29 colon adenocarcinoma cells. J. Clin. Invest. 96: 491-503, 1995.
37. Singh, J., C. V. Rao, N. Kulkarni, B. Simi, and B. S. Reddy. Molecular markers as intermediate endpoints in chemoprevention of colon cancer: modulation of ras activation by sulindac and phenylhexylisothiocyanate (PHITC) during colon carcinogenesis. Int. J. Oncol. 5: 1009-1018, 1994.
38. Skinner, S. A., A. G. Penney, and P. E. O'Brien. Sulindac inhibits the rate of growth and appearance of colon tumours in the rat. Arch. Surg. 126: 1094-1096, 1991.
39. Smalley, W. E., and R. N. DuBois. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv. Pharmacol. 39: 1-20, 1997.
40. Stopera, S. A., L. C. Murphy, and R. P. Bird. Evidence for a ras gene mutation in AOM-induced colonic aberrant crypts in Sprague-Dawley rats: earliest recognisable precursor lesions of experimental colon cancer. Carcinogenesis 13: 2081-2085, 1992.
41. Thompson, H. J., C. Jiang, J. Lu, R. G. Mehta, G. A. Piazza, N. S. Paranka, R. Pamukcu, and D. J. Ahnen. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res. 57: 267-271, 1997.
42. Thun, M. J., M. M. Namboodiri, E. E. Calle, W. D. Flanders, C. W. Heath. Aspirin use and risk of fatal cancer. Cancer Res. 53: 1322-1327, 1993.
43. Vivona, A. A., B. Shpitz, A. Medline, W. R. Bruce, K. Hay, M. A. Ward, H. S. Stern, and S. Gallinger. K-ras mutations in aberrant crypt foci, adenomas, and adenocarcinomas during azoxymethane-induced colon carcinogenesis. Carcinogenesis 14: 1777-1781, 1993.
44. Vogelstein, B., E. R. Fearon, S. R. Hamilton, S. E. Kern, A. C. Preisinger, M. Leppert, Y. Nakamura, R. White, A. M. Smits, and J. L. Bos. Genetic alterations during colorectal tumor development. N. Engl. J. Med. 319: 525-532, 1988.
45. Ward, R. L., A. V. Todd, F. Santiago, T. O'Connor, and N. J. Hawkins. Activation of the K-ras oncogene in colorectal neoplasms is associated with decreased apoptosis. Cancer 79: 1106-1113, 1997.